We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Shedding Light on Novel Cellular Pathways with TTP LabTech

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

TTP LabTech has highlighted the use of the Acumen® eX3 laser scanning imaging cytometer to elucidate novel cellular pathways involved in the shedding of the epidermal growth factor receptor (EGFR).

The application note entitled “The use of Acumen eX3 for the identification of the roles of Protein Kinase C (PKC) α & δ isoforms in PMA-induced ectodomain shedding” describes how the high throughput imaging technology of the Acumen eX3 accurately and sensitively quantifies and monitors protein expression levels.

Online image capture and analysis, as well as multiplexing capabilities, allows the Acumen eX3 platform to provide consistent and accurate data from complex biological systems.

The shedding of HB-EGF is classically controlled by a disintegrin and metalloproteinase, ADAM17. The imaging technology of Acumen eX3 was used to determine the contributions of additional enzymatic pathways in this process.

HT1080 cells, transfected with a modified, alkaline phosphatase linked, heparin binding EGFR (AP-HB-EGF) were examined by both the traditional enzymatic assay and immunofluorescence for receptor shedding in the presence and absence of inhibitors of ADAM17 and PKC isoforms.

Experimental data suggest that important contributions are made by the PKC isoforms α & δ. Disruption of EGFR homeostasis is associated with a number of important cancer targets, notably breast, lung and colon tumours. Consequently research of this type is vital to further the fight against these diseases.